Dingdang Health Technology Group (9886) H2 2024 earnings summary

Executive summary

• FY2024 revenue fell 3.9% YoY to RMB4,669.1m; net loss widened 64.6% to RMB380.0m, including RMB205.8m of goodwill and intangible-asset impairments. Adjusted net loss narrowed 32.0% to RMB57.2m.

• Gross margin improved to 32.9% from 31.1%, supported by procurement efficiency and sales mix; cash and cash equivalents were RMB1,218.0m at year-end.

Financial highlights

• Revenue was RMB4,669.1m versus RMB4,856.8m in 2023; pharmaceutical and healthcare revenue declined 3.8% to RMB4,539.6m.

• Gross profit rose to RMB1,538.3m from RMB1,510.7m as cost of revenue fell 6.4% to RMB3,130.7m.

• Net loss was RMB380.0m versus RMB230.9m; loss attributable to owners was RMB376.5m versus RMB225.8m.

• Adjusted net loss was RMB57.2m versus RMB84.2m; adjusted net loss margin improved to 1.2% from 1.7%.

Outlook and guidance

• Strategy centers on deepening smart-pharmacy coverage in Beijing, Shanghai and Shenzhen, improving service density, supply chain and fulfillment, and extending online national medical-insurance purchases.

• Plans include applying AI to upgrade digital health services and strengthening the integrated Treatment, Diagnosis, Pharmaceutical Products and Medical Insurance ecosystem; no numeric FY2025 guidance was stated.